- Report
- February 2022
- 40 Pages
Germany
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
Ireland
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
Japan
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
Russia
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
South Korea
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
United States
From €1417EUR$1,500USD£1,205GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €1417EUR$1,500USD£1,205GBP
- Report
- November 2022
- 335 Pages
Global
From €3371EUR$3,570USD£2,868GBP
Prostacyclin is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary arterial hypertension, deep vein thrombosis, and coronary artery disease. It works by inhibiting platelet aggregation and reducing the risk of blood clots. Prostacyclin is typically administered intravenously or subcutaneously, and is available in both generic and branded forms. It is also used in combination with other drugs to treat certain conditions.
The prostacyclin market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. These companies include Actelion Pharmaceuticals, Bayer AG, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more